BAY3546828 (Actinium-225-macropa-pelgifatamab)
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for BAY3546828 (Actinium-225-macropa-pelgifatamab), covering 2026-04-17 to 2026-04-17. Get the full timeline:
Most recent: Clinical Trial Update: A Study to Learn How Safe the Study Treatment Actinium-225-macropa-pelgifatamab (BAY3546828) is, How it Affects the Body, How it Moves Into, Through and Out of the Body, and About Its Anticancer Activity in Participants With Advanced Metastatic Castration-resistant Prostate Cancer (mCRPC) [Phase 1]